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1. Abstract 
 
The von Willebrand factor (VWF) is a key factor in the blood coagulation system. 
It binds platelets to collagen fibres of ruptured vessel walls. Patients with von 
Willebrand desease have a decreased VWF level in their blood or mutations in 
their VWF protein leading to dysfunction. For these patients, it is vital to receive 
VWF substitutes. 
 
This diploma thesis investigates the platelet adhesion properties of five different 
VWF substitutes: (a) plasma-derived VWF/factor VIII concentrate 
(Immunate#09HZ2000I), (b) Pro-recombinant VWF 298, (c) mature recombinant 
VWF 158, (d) plasma-derived VWF 09/47, (e) plasma-derived VWF 07 42/3. 
These concentrates were tested in their pure version and with addition of 
recombinant and plasma-derived factor VIII. 
The experiments were carried out in a flow chamber system, simulating the blood 
flow through a ruptured blood vessel. A solution containing erythrocytes, 
platelets, buffer, and the VWF concentrate was used as blood imitation. Collagen-
coated glass plates functioned as the ruptured vessel wall, while a pump ensured a 
proper wall shear stress rate. Clots of platelets on the glass plates were 
subsequently visually detected and counted by a computer programme.  
 
The results indicate that the plasma-derived VWF/factor VIII concentrate 
(Immunate#09HZ2000I) and the plasma-derived VWF 09/47 performed best. The 
addition of factor VIII did not noticeably influence the platelet adhesion 
properties.  In the light of the scattering results and the influence of individual 
blood samples from unknown donors, the results are unsteady and need to be 
verified.  
  1
Zusammenfassung 
 
Der Von Willebrand Faktor (VWF) ist einer der wichtigsten Faktoren des 
Blutgerinnungssystems.  Er bindet Thrombozyten an die Kollagenfasern von 
rupturierten Gefäßwänden. Patienten, die unter der Von Willebrand Krankheit 
leiden, haben entweder zu geringe VWF Konzentrationen im Blut oder durch 
Mutationen veränderte VWF-Funktionen. Für diese Patienten ist VWF 
Substitution lebensnotwendig. 
 
Diese Diplomarbeit untersucht die Thrombozytenadhäsion von fünf 
verschiedenen VWF Konzentraten: (a) plasmagereinigtes VWF/Faktor VIII 
Konzentrat (Immunate#09HZ2000I), (b) Pro-rekombinater VWF 298, (c) reifer 
rekombinanter VWF 158, (d) plasmagereinigter VWF 09/47, und (e) 
plasmagereinigter VWF 07 42/3. Diese Konznetrate wurden ohne und mit Zusatz 
von rekombinantem und plasmagereinigtem Faktor VIII auf ihre 
Thrombozytenbindung hin untersucht. 
Die Experimente wurden mit Hilfe eines Flusskammersystems getestet, welches 
den Blutfluss durch ein verletztes Blutgefäß simulierte. Als Untersuchungslösung 
wurden Erythrozyten, Thrombozyten, eine Pufferlösung und das jeweilige VWF 
Konzentrat gemischt. Diese Mischung diente als Blutersatz. Glasplättchen wurden 
mit Kollagen beschichtet um die zerstörte Gefäßwand zu imitieren, während eine 
Pumpe für die richtige Scherspannung eines rupturierten Gefäßes sorgte. 
Anschließend wurden die kollagenbeschichteten Glasplättchen gefärbt und die 
gebildeten Thromben wurden mittels eines Bildverarbeitungsprogramms gezählt 
und ausgewertet. 
 
Die Ergebnisse zeigen, dass das plasmagereinigte VWF/Faktor VIII Konzentrat 
(Immunate#09HZ2000I) und der plasmagereinigte VWF 09/47 die beste 
Thrombozytenadhäsion  erzielen. Die manuelle Zugabe von Faktor VIII hat die 
Thrombozytenadhäsionseigenschaften der Konzentrate nicht wesentlich 
beeinflusst. Die Ergebnisse sind aber nicht eindeutig und unterliegen teils hohen 
Schwankungen. Diese stammen unter anderem von den verschiedenen 
Blutproben, die von anonymen Spendern kamen. 
  2
2. Introduction 
 
 
The aim of this thesis was to investigate different Von Willebrand factor 
concentrates concerning their platelet adhesion abilities. Patients suffering from 
von Willebrand disease need such concentrates to balance their von Willebrand 
factor levels, which are decreased because of von Willebrand factor dysfunction 
or severely decreased levels of von Willebrand factor in their blood system. In 
this work five differently produced von Willebrand factor concentrates, both, 
plasma derived, including one commercially available drug product, and 
recombinant ones, were tested and compared. These von Willebrand factor 
concentrates were all produced by Baxter BioScience. 
In order to test the platelet adhesion ability of the different VWF samples a flow 
chamber was used. The glass plate inserted into the flow chamber was coated 
with inactivated collagen to imitate the ruptured blood-vessel wall. A solution, 
containing erythrocytes, platelets, buffer and the von Willebrand factor sample, 
was mixed and functioned as a blood imitation. This blood was then pumped 
through the flow chamber, where the connected pump was programmed to imitate 
the shear stress of a ruptured vessel. After the experiment, photos of the glass 
plates were made and the formed blood clots were detected by a computer 
programme that calculated the blood-clot-covered surface of the glass plates. 
Due to the fact that most of the patients suffering from von Willebrand disease 
also have decreased factor VIII levels, the tested von Willebrand factor 
concentrates were mixed with factor VIII concentrates to investigate eventual 
additive or subtractive effects in the von Willebrand factor platelet adhesion 
ability. Finally, two different von Willebrand factor concentrates were mixed and 
tested.  
This diploma thesis is organised as follows: Section 3 provides an overview of the 
theory of haemostasis, which describes the background of the experiments. In 
Section 4, the materials and the flow-chamber method are described in detail. 
Section 5 summarises the obtained results and compares the different von 
Willebrand factor concentrates. In Section 6 the results are discussed and 
conclusions are drawn. 
  3
3. Theory 
 
In this section, the physical and biological process of haemostasis are explained, 
which is simulated in the experiments carried out for this thesis. The two 
investigated clotting factors that are important for haemostasis are the von 
Willebrand factor (VWF) and factor VIII, which are both described in detail in 
this chapter. 
 
 
3.1. Haemostasis 
 
“Blood coagulation and platelet-mediated primary haemostasis have evolved as 
important defence mechanisms against bleeding. The coagulation system is 
triggered in response to rupture of endothelium, which allows exposure of blood 
to the extravascular tissue. The responses of the coagulation system are 
coordinated with the formation of the platelet plug that initially occludes the 
vascular lesion. Anticoagulant mechanisms ensure careful control of coagulation 
and, under normal conditions, they prevail over the procoagulant forces. 
Disturbances of the natural balance between the procoagulant and anticoagulant 
systems due to generic or acquired factors may result in bleeding or thrombotic 
diseases.” [1] 
 
Factor I Fibrinogen 
Factor II Prothrombin 
(Factor III) Tissue Thromboplastin 
(Factor IV) Calcium ions 
Factor V Labile Factor 
Factor VII Stable Factor 
Factor VIII Antihemophilic Factor 
Factor IX Christmas Factor, or 
Plasma Thromboplastin Component 
(PTC) 
Factor X Stuart-Prower Factor 
Factor XI Plasma Thromboplastin Antecedent 
(PTA) 
Factor XII Hageman Factor 
Factor XIII Fibrin Stabilizing Factor 
 
Figure 1. List of clotting factors involved in the blood coagulation 
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The process of blood coagulation is very complex. According to the specific 
reactions the process of haemostasis can be subdivided into four main phases: (a) 
the activation of clotting, followed by (b) the process of clotting, divided into the 
intrinsic and extrinsic pathway, then (c) the regulation of clotting and finally (d) 
the dissolution of the clot, the fibrinolysis.  
The initial event activating the coagulation system is the damage of endothelial 
cells, where matrix proteins, such as collagen and fibronectin are exposed to the 
blood system. This is followed by vascular constriction to limit the flow of blood 
in the area of injury. In order to build a clot, platelets must first adhere to the 
exposed collagen, then release the contents of their granules, and finally, 
aggregate. The mediator between platelets and the endothelial surface is the von 
Willebrand’s factor (VWF), which acts as a bridge between these two. Parallel to 
platelet adhesion the clotting cascades are activated.  
 
 
Figure 2. Reaction cascade of blood coagulation 
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The intrinsic pathway leads to fibrin formation based on the activation of factor 
XII, resulting in the activation of factor X, to translate prothrombin into thrombin. 
Meanwhile, the extrinsic pathway also activates factor X after the formation of an 
activated tissue factor-factor VIIa complex leading to the production of fibrin. 
 
 
3.1.1. Intrinsic pathway 
 
As shown in Figure 2, the intrinsic pathway is initiated when prekallikrein, high-
molecular-weight kininogen, factor XI, and factor XII are exposed to a negatively 
charged surface. This results in the conversion of prekallikrein to kallikrein, 
which then activates factor XII to factor XIIa. Furthermore, a reaction cascade is 
activated leading to the activation of factor XI and the release of bradykinin from 
high-molecular-weight kininogen. Factor XIa converts factor IX into its activated 
form in the presence of Ca2+. Factor VIII circulates bound to the von Willebrand 
factor. After activation, factor VIIIa dislocates and acts as a receptor for the 
factors IXa and X on the surface of activated platelets. Again, the presence of 
Ca2+ is required to activate factor X into factor Xa. This is where the intrinsic and 
the extrinsic pathway converge. 
 
 
3.1.2. Extrinsic pathway 
 
The activation of the extrinsic pathway starts with the release of factor III and the 
tissue factor. Then factor III converts factor VII into its activated form. In the 
presence of Ca2+ factor VIIa activates factor X. At the activated factor X, the two 
pathways meet. An additional link between the extrinsic and the intrinsic pathway 
exists trough the ability of tissue factor and factor VIIa to activate factor IX.  
The main point in these both pathways is the translation of factor X into factor 
Xa, which activates thrombin from prothrombin. To initiate the building of fibrin, 
the protease thrombin cleaves the A and B chains of fibrinogen.  
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The fibrin monomers finally build long strands, which leads to the formation of 
an unstable clot. Factor XIIIa, activated by thrombin, is a transglutaminase that 
stabilises the clot by covalent crosslinking of fibrin.  
 
 
 
Figure 3. Blood clot 
 
 
The fibrin monomers finally build long strands, which leads to the formation of 
an unstable clot. Factor XIIIa, activated by thrombin, is a transglutaminase that 
stabilises the clot by covalent crosslinking of fibrin.  
Plasmin, a serine protease that circulates as the inactive proenzyme plasminogen, 
is responsible for the degradation of fibrin clots. 
 
 
3.1.3. Haemophilia 
 
Haemophilia, one of the most common inherited bleeding disorders, is caused by 
defects in the process of haemostasis. There are two forms of haemophilia, 
haemophilia A and B.  
Haemophilia A, or classic haemophilia, is a bleeding disorder resulting from a 
deficiency in factor VIII. Depending on the remaining level of factor VIII in the 
blood system, there are the severe, the moderate, and the mild forms of 
haemophilia A. Patients with deficiencies of factor VIII suffer joint and muscle 
haemorrhage, easy bruising and prolonged bleeding from wounds. Treatment of 
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haemophilia A is accomplished by infusion of factor VIII concentrates prepared 
either from human plasma or from recombinant DNA technology. 
Haemophilia B on the contrary results from deficiencies in factor IX. The patients 
also suffer from decreased factor IX clotting activity and prolonged coagulation 
time.  
 
3.2. Platelets 
 
Platelets are the smallest, but the most numerous cells in blood among the other 
two major types of blood cells (erythrocytes and lymphocytes). Platelets are small 
cytoplasmic bodies with a diameter of 1.5-4µm and a thickness of 0.5-2µm. 
Platelets have, similar to red blood cells, no nucleus. The normal platelet count is 
160,000-300,000 per µl of blood [2], but numbers differ slightly according to the 
source of literature. Since platelets are so small, they make up just a tiny fraction 
of the whole blood volume.  
 
 
 
 
Figure 4. Genesis of platelets 
 
 
Platelets are produced from megakaryocytes in the bone marrow as shown in 
Figure 4. These megakaryocytes undergo a process of fragmentation that results 
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in the release of over 1,000 platelets per megakaryocyte. The lifespan of platelets 
is approximately up to two weeks in a healthy organism. 
Inside, platelets contain numerous granules, which are, according to their 
function, divided into three main granules (a) α-granules, (b) dense granules and 
(c) lysosomes. Inside α-granules there are proteins, especially fibrinogen and 
fibronectin, growth factors, such as platelet-derived growth factor (PDGF) and 
transforming growth factor (TGF-β), besides various clotting factors. The dense 
granules mainly contain low-molecular substances, such as nucleotides, metal 
ions and serotonin. Lysosomes contain acid hydrolases.  
Platelet activation results in spilling of the contents of the granules into the blood. 
As mentioned above, platelets are essential for haemostasis and blood 
coagulation.  
Platelet adhesion is triggered by the simultaneous binding of (a) the adhesion 
protein of VWF to the glycoprotein-Ib/IX-complex of platelets and (b) to the 
exposed collagen fibrils. When the platelts bin to the collagenous surface, the 
platelets form a clot, which is stabilised by fibrinogen. The clot finally closes the 
wound and due to platelet contraction the wound contracts. 
  
 
 
Figure 5. Activated platelets 
 
Generally, low platelet counts increase bleeding risks and high platelet counts 
may lead to thrombosis. In some cases the platelet count is within a healthy range, 
but the platelets are dysfunctional. For instance, various pharmaceutical drugs, 
such as aspirin, irreversibly disrupt platelet function by inhibiting 
cycolooxygenase-1 (COX 1) and hence the normal haemostasis. 
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3.3. Von Willebrand factor 
The von Willebrand factor was discovered by Dr. Erich von Willebrand (1870-
1949) in 1926. He was a doctor in Finland, who first described a hereditary 
bleeding disorder in families from the Åland islands, who had a tendency for 
mucosal bleeding, which he named “hereditary pseudo-haemophilia”. In the 
1970s, the VWF was purified for the first time. 
“Von Willebrand factor (VWF) is a blood glycoprotein that is required for normal 
haemostasis, and deficiency of VWF, or von Willebrand disease (VWD), is the 
most common inherited bleeding disorder. VWF mediates the adhesion of 
platelets to sites of vascular damage by binding to specific platelet membrane 
glycoproteins and to constituents of exposed connective tissue. These activities 
appear to be regulated by allosteric mechanisms and possibly by hydrodynamic 
shear forces. VWF also is a carrier protein for blood clotting factor VIII, and this 
interaction is required for normal factor VIII survival in the circulation.” [3] 
 
 
 
 
Figure 6. Von Willebrand factor binding platelets to collagen 
 
 
 
 
 
 10
3.3.1. Biosynthesis and structure of von Willebrand factor 
According to [3-5], VWF is synthesised in endothelial cells and is stored in 
intracellular organelles and the Weibel-Palade bodies, or secreted. Additionally, 
the VWF is also synthesised in the megakaryocytes, where it is stored in the α-
granules. Endothelial cells release the VWF as large multimers, which then 
circulate in the plasma as a series of high-molecular-weight multimers. These 
mulitmers are generated by proteolysis and shear stress enhances the sensitivity to 
proteolytic cleavage.   
 
Figure 7. Structure of the von Willebrand factor 
 
As shown in the Figure 7, each VWF subunit shows a characteristic pattern of 
homologous A, B, C and D domains, which are independent building blocks in 
many other proteins [6]. The propeptide contains a D1 and D2 domain. The 
mature subunit consists of D’-D3-A1-A2-A3-D4-B1-B2-C1-C2 domains and a C-
terminal part of 151 amino acids that has no internal homology. The subunit 
apparently contains both a rod domain and a globular domain and corresponds to 
one half of the protomer. The protomer consists of two identical monomer 
subunits linked by disulfide bonds at the C terminus. The disulfide bonds in the 
amino-terminal globular ends link promoters to form VWF multimers. The A3 
subunit of the VWF is responsible for the collagen binding during haemostasis, 
whereas the VWF A1 domain binds to the glycoprotein-Ib-alpha (Gp-Ibα) domain 
on the surface of platelets. These two regions are relevant for the VWF adhesion 
properties investigated in this diploma thesis. The total structure of the VWF 
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protein is yet unknown, but the three-dimensional structures of the VWF-A3 and 
the VWF-A1 domains are shown in Figure 8. 
 
                                     
   (a)      (b) 
Figure 8. Ribbon drawings of (a) the crystal structure of the collagen binding 
VWF-A3 domain, (b) Schematic representation of the complex of GpIb  (green) 
and the VWF-A1 domain (blue).  
 
3.3.2. Function of von Willebrand factor 
At high wall shear stress rates, platelet adhesion is mediated almost completely by 
the VWF, whereas at low wall shear stress rates platelet adhesion is independent 
of the VWF. The role of the VWF is mainly to both form a bridge between its A1 
domain and platelets, and to bind to the collagenous surface through its A3 
binding domain. Additionally, the VWF contains binding sites for heparin, 
ristocetin, botrocetin and sulfatides. Furthermore, the VWF serves as carrier 
protein for factor VIII. Bound to the VWF, factor VIII is protected against 
binding to membrane surfaces and to proteolytic attack by various serine 
proteases such as activated protein C. Due to its essential role in haemostasis, 
mutations or deficiencies of the VWF lead to severe malfunctions in the human 
platelet adhesion and coagulation system. 
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3.3.3. Von Willebrand factor and factor VIII 
Factor VIII is an essential clotting factor, which acts as cofactor for factor IXa. In 
the presence of Ca2+ and phospholipids, factor VIIIa and factor IXa form a 
complex to activate factor X. In [6], the authors discuss that haemophilia A can be 
cured in factor VIII-deficient dogs and humans by liver transplantation, which 
suggests that the liver is the major site of factor VIII synthesis. Factor VIII 
contains three distinct domains arranged in the order A1-A2-B-A3-C1-C2 as 
shown in Figure 9. The C domains are capable of binding negatively charged 
phospholipids, whereas the B domain is essential for VWF binding. Factor VIII 
also contains two acidic regions. The first one, located between A1 and A2, is 
important for the procoagulant activity. The second acidic region, which is 
between B and A3, is required for the association of factor VIII with VWF.  
 
 
Figure 9. Resemblance of factor VIII and factor V 
 
In plasma, factor VIII is stabilised and protected from degradation because of its 
association with the VWF molecule. The light chain of factor VIII interacts 
noncovalently with the N-terminal region of the VWF protein. The half-life of 
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factor VIII in the presence of normal VWF is approximately 12 hours, whereas its 
half-life is reduced to 2 hours in the absence of VWF. [7]                        
 
 
3.3.4. Von Willebrand Disease 
The Von Willebrand Disease is a genetic disease that can be inherited from either 
parent.  It affects males and females equally.  A man or woman with VWD has a 
50% chance of passing the gene on to his or her child. As discussed in [8], 
hereditary bleeding disorders such as the VWD are more common in countries 
with a high rate of consanguinity and a large number of births per family. A 
family history of a bleeding disorder is the primary risk factor. Approximately 
one out of 100 people are affected with VWD, which makes it the most common 
bleeding disorder. VWD results from a quantitative or qualitative deficiency of 
VWF. The importance of specific regions of VWF, which interact with other 
proteins of the coagulation cascade, has led to the classification of three subtypes 
of VWD: (a) based upon quantitative deficiencies (type 1 and 3), and (b) based 
upon qualitative deficiencies (type 2). Type 1 is the mildest and most common 
form of VWD. Patients have low levels of VWF and may also have deficiencies 
in factor VIII as well. Type 2 is characterised by mutations in the VWF protein, 
which lead to malfunction. Of the five known subtypes of type 2 (A, B, C, M, N), 
type 2A is the most common one and is characterised by a relative reduction in 
intermediate and high-molecular-weight multimer complexes. The most severe 
form of VWD is Type 3, where patients suffer from a total lack of VWF, and the 
factor VIII levels are often less than 10% resulting in secondary haemophilia. 
People suffering from VWD bruise easily, have recurrent nosebleeds and bleed 
after tooth extraction, tonsillectomy and other surgery. One possible treatment is 
desmopressin, which causes a temporary increase in the VWF levels. As pointed 
out in [9], patients with VWD who cannot be treated with desmopressin 
exclusively most frequently require substitution of both VWF and factor VIII.   
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4. Materials and Method 
The aim of this diploma thesis was to observe the different platelet adhesion 
abilities of various VWF concentrates. For that a flow-chamber system was used.  
This flow-chamber experiment was an ex-vivo blood coagulation study, where the 
flow chamber simulated a blood vessel and the attached pump imitated the normal 
blood flow under shear stress. An erythrocyte-platelet-buffer solution was used to 
imitate blood, and was mixed directly before the flow-chamber experiment was 
started. Herein, various VWF concentrates were tested in order to evaluate their 
platelet adhesion properties in the blood flow. To carry out the flow-chamber 
experiment the following equipment and reagents were needed. 
 
4.1. Equipment  
• Flow Chamber System, Cat: 303 0000, Oligene 
• Silicon gasket (0.3mm), Cat: 303 0541, Oligene 
• Cover slips, diameter 25mm, Cat: 303 0522, Oligene 
• Clip on spring, Cat: 303 0510, Oligene 
• Pump, type: Ismatec IPC, Cat: ISM935, #03763-00097 
• Centrifuge Sorvall RC3B, Rotor H4000 
• Cellcounter Sysmex, #pocH-100i 
• Microscope Olympus BX60 
• Digitrace, IMATEC elektro. Bildanalyse GmbH (1998) 
 
4.2. Reagents 
Table 1 shows the used reagents and their preparation. The buffers were prepared 
one day in advance, except for the 4% HSA-Krebs Ringer buffer, the 
Acetylsalicylicacid-buffer (ASA-buffer) and the Glutaraldehyde fixation buffer, 
which were prepared on the day of the experiment. 
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Acetic acid 0.1M        
Kollagenreagens Horm 1mg, Nycomed, # 10261165 (collagen reagent) 
Krebs Ringer buffer pH 7.35   for 1l: 
107mM NaCl, Merck p.a. #K34684504520 6.25 g 
20mM NaHCO3, Merck p.a. #K22116029 543 1.68 g 
4mM KCl, Merck p.a. #821 TA499533  0.30 g 
2mM Na2SO4, Merck p.a. #007 TA777649 0.28 g 
19mM Tri-Na-Citrat.2H2O, Merck p.a. #A570148 442 5.59 g 
2.5 mM CaCl2.2H2O, Merck p.a. #912 TA642982 0.37 g 
0.5 % Glucose.H2O, Merck for biochem #620 K1261442 5 g 
HEPES/NaCl bufferpH 7.35   for 1l: 
10mM HEPES, Merck buffer substance #K91648610 941 2.38 g 
150mM NaCl, Merck p.a. #K31900304 314 8.77 g 
4% HSA-Krebs Ringer buffer     
Krebs Ringer pH 7.35 + 20% HSA     
Krebs Ringer buffer pH 6.5, without calcium for 1l: 
107mM NaCl, Merck p.a. #K34684504520 6.25 g 
20mM NaHCO3, Merck p.a. #K22116029 543 1.68 g 
4mM KCl, Merck p.a. #821 TA499533  0.30 g 
2mM Na2SO4, Merck p.a. #007 TA777649 0.28 g 
19mM Tri-Na-Citrat.2H2O, Merck p.a. #A570148 442 5.59 g 
0.5 % Glucose.H2O, Merck for biochem #620 K1261442 5 g 
TBS pH 7.4      for 1l: 
150mM NaCl, Merck p.a. #K31900304 314 8.77 g 
20mM Tris, Merck buffer substance #239 K17260582 2.43 g 
100mM Acetylsalicylicacid (ASA-buffer) for 1ml EtOH: 
Acetylsalicylicacid 100mM in Ethanol   18mg ASA 
Glutaraldehyde #126H1444, Cat: G-6257, Sigma   
Fixation buffer pH 7.2: Buffer tablets PH 7.2 TP221168, Cat: 9468 
dissolve 1 tablet in 1 litre a.d.      
Human Albumin 20%, Baxter, #0107400H   
Acetylsalicylicacid, #55H0294, Sigma, Cat:A-5376   
Ethanol 96%, #K34220471 503, Merck, 
Cat:1.00971.2500   
May-Grünwald staining solution     
dissolve 0.25 g dye #L194952 Merck 1352 in 100ml Methanol  
Merck K25094709817 at +60°C for 60min-> filtrate 2 x after 24 hrs.  
Table 1. List of reagents and buffer preparation 
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4.3. Test articles 
• Plasma derived VWF/factor VIII- Concentrate, Immunate#09HZ2000I 
[10] 
• Pro-recombinant-VWF 298 (Pro-rVWF 298)  
• Mature recombinant VWF 158 (mature-rVWF 158) 
• Plasma-derived VWF 09 (pd-VWF 09) 
• Plasma-derived VWF 07 42/3 (pd-VWF 07 42/3) 
• VWF SEC 06 
 
4.4. Procedure 
The procedure was always carried out in the same way, following exactly the 
same protocol for each experiment. The experiment was prepared as follows: 
First, the buffer solutions were prepared, and the glass plates were coated with 
collagen one day in advance. Then, the platelet and the erythrocyte concentrates 
were diluted, washed, and mixed to create the blood imitation. Afterwards the 
samples of different VWF concentrates were prepared and added to the blood 
imitation, and the flow chamber perfusion experiment was started. Subsequently, 
the glass plates were stained and then left to dry over night. Finally the stained 
glass plates were detected under the microscope using a calculation program on a 
computer. The individual steps of this experiment are detailed in the following 
paragraphs. 
 
4.4.1. Coating 
The glass plates were coated with collagen reagent (0.5mg collagen reagent + 
0.05M acetic acid) one day before the actual experiment was carried out. 
Therefore 150µl of the collagen reagent was pipetted on each glass plate. Then, 
the coated glass plates were left to dry in the refrigerator at +4 °C for at least 12 
hours. 
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4.4.2. Preparation of platelets 
The platelets used were provided by The Red Cross, Austria. First, the platelets 
were filled into a special glass for centrifugation, then the Krebs Ringer buffer 
w/o calcium, pH=6.5, was added in equal parts. The ASA stock solution was 
diluted 1:100 with the Krebs Ringer buffer, pH=6.5. From this 1mM ASA buffer 
about 1% (related to the platelet solution) was added to the platelet solution. 
Afterwards the platelet-buffer-solution was centrifuged at 2200 rpm for 10 
minutes at 10°C without break. Then the supernatant was discarded and the 
remaining pellet of platelets was dissolved in Krebs Ringer buffer pH=7.35. 
Finally, the platelet number was counted. The platelet number should lie between 
approximately 1000x103 and 2000x103. During the experiment, unused platelets 
were kept cool in an ice bath. 
 
  
Figure 10. Haematocrit and Platelet count 
In Figure 10 two typical prints of the platelet counts and the haematocrit are 
shown, using the cell counter Sysmex #pocH-100i. 
 
4.4.3. Preparation of erythrocytes 
The erythrocytes were also provided by The Red Cross, Austria. First, the 
erythrocytes were filled into a specific glass made for centrifugation and then 
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diluted with the HEPES/NaCl buffer, pH=7.35, in equal parts. Afterwards the 
solution was centrifuged at 2000rpm for 10 minutes at 10°C without break. The 
supernatant was discarded and the remaining erythrocytes were washed in the 
Krebs Ringer buffer, pH=7.35. Then, the gained solution was again centrifuged, 
this time at 2200rpm for 10 minutes at 10°C without break. Finally, the 
haematocrit (HCT) was measured. The HCT should be over 60%. During the 
experiment, unused erythrocytes were cooled in an ice bath. 
 
4.4.4. Preparation of samples for testing 
The calculated amount of erythrocytes, platelets, the 4% HAS-Krebs Ringer 
buffer solution and the sample are mixed and incubated for 10 minutes at 37°C. In 
this study, three concentrations of each sample were tested: (a) 0.5 U/ml, (b) 1 
U/ml, and (c) 2 U/ml. The exact amount of the sample was calculated as follows:  
250000)  /lper  (platelets
solution sample of  volumetotalplatelets of volume μ=  
35.0)  /%in  (HCT
solution sample of  volumetotaleserythrocyt of volume =  
ion)concentrat  /in U/ml Ag:(VWF
solution sample of  volumetotalsample of volume =  
The total sample mix was 1.5ml. The amount of platelets depended on the platelet 
count of the concentrate. The amount of erythrocytes was calculated in proportion 
to the measured HCT. The correct shear rate, γ , was calculated as follows:  
03.16 2 ⋅= ab
Qγ , 
where  denotes the flow rate in ml/s, Q cm 2.0=a and cm 03.0=b denote the 
slight width and height, respectively. Table 2 shows a typical experiment 
calculation file. 
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Flow chamber experiment, 06.08.2006
MIX: 1,5 ml total
MIX (ml) MIX Soll
Platelets 0,22 250000 platelets/µl 1703000
Erythrocytes 0,75 35,0 HCT % 69,9
Sample 0,53
Concentration (AgU/ml)
Concentration (AgU/ml)
2 1 0,5
VWF:Ag 8 4
Samples U/ml
sample ml HSA-KR ml sample ml HSA-KR ml
rVWF 299 15,7 0,764             0,236-           0,382         0,147           
rVWF 343 36,8 0,326             0,203           0,163         0,366           
rVWF 158 67,6 0,178             0,351           0,089         0,440           
VWF pd 07 42/3 Eluat 1 n. Dial. + MT 58 0,207               0,322           0,103           0,425           
Immunate #09HZ2000I 115 0,104               0,424           0,052           0,477           
VWF:Ag 3 2,5
Samples U/ml
sample ml HSA-KR ml sample ml HSA-KR ml sample ml HSA-KR ml sample ml HSA-KR ml sample ml HSA-KR ml
rVWF 299 15,7 0,287               0,242           0,239           0,290           0,191          0,338           0,096           0,433           0,048          0,481       
rVWF 298 35,7 0,122             0,406           0,102         0,427           0,082        0,447           0,041           0,488           0,020        0,508       
rVWF 158 67,6 0,067             0,462           0,055         0,473           0,044        0,484           0,022           0,507           0,011        0,518       
VWF pd 07 42/3 Eluat 1 n. Dial. + MT 58 0,078             0,451           0,065         0,464           0,052        0,477           0,026           0,503           0,013        0,516       
Immunate #09HZ2000I 115 0,039             0,490           0,033         0,496           0,026        0,503           0,013           0,516           0,007        0,522       
Calculation of shear rate:
Shear rate ≅ = 6Q/(ab2) * 1.03 
Q (flow rate, ml/sec) 
a  (slight width, cm) a = 0.2 cm
b  (slight height, cm) b = 0.03 cm
 
Table 2. Example of a calculation file for the volume and concentration of 
samples 
 
4.4.5. Perfusion in the flow chamber 
Before the actual perfusion experiment could be started, the water bath was filled 
and heated up to 37°C to imitate body temperature. The pump was programmed 
to imitate the correct shear stress of a ruptured blood vessel. Then the collagen 
coated glass plates were put into the flow chamber, layered with a silicon gasket, 
and fixed with a clip on a spring as shown in Figure 11.  
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Figure 11. Preparation of the flow chamber 
Every experiment was carried out as a double determination, where two flow 
chambers were used in parallel in the same system. Some of these experiments 
were also carried out multiple times. The setup of the experiment is shown in 
Figure 12. The flow chambers, readily equipped with the coated glass plates, were 
put into the water bath. Then, Tube A was put into the sample vial and connected 
to flow chamber 1, Tube B connected the two flow chambers, and Tube C went 
from flow chamber 2 to the pump. Finally Tube D came from the pump and went 
back into the sample vial. Simultaneously, the timer was set, and the pump was 
started. The sample solution circulated for 4 minutes. 
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Figure 12. Set up of the flow chamber experiment 
 
4.4.6. Staining 
After four minutes of blood circulation, the pump was stopped and the glass 
plates were taken out of the flow chamber. Then they were put into the 
glutaraldehyde buffer (0.5% glutaraldehyde diluted in TBS buffer) for 20 
minutes, to fix the clots on the surface. Afterwards the glass plates were laid out 
on paper and left to dry over night, for at least 12 hours at room temperature. 
After drying, 150µl of the May-Grünwald staining solution were pipetted on each 
glass plate and left there to react for exactly one minute at room temperature. If 
the solution was left on the surface for longer than one minute, the staining got 
too dark for proper detection. After staining, 150µl of the fixation buffer solution, 
pH=7.2, were added on each plate to dilute the staining solution. The mixture was 
left on the plates for two minutes. After that the glass plates were washed with 
buffer solution and left to dry at room temperature. 
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4.4.7. Detection 
For detection, the stained glass plates were put under the microscope. The 
programme “Digitrace” (IMATEC elektro. Bildanalyse GmbH) counted the clots 
on the collagen-coated surface of the glass plates. Twelve pictures of each glass 
plate were taken, at which the segmentation parameters were set to 0/117 in the 
programme. The light intensity was set to 10.5. After the pictures were taken, the 
programme counted the clotted surface and calculated the percentage of the 
clotted area of the glass plate. The mean value of these twelve pictures was taken 
and the percentage of plate coverage was used to compare the binding abilities of 
the different samples. The result was blank-value corrected and stored for further 
evaluation. 
  
Figure 13. Blood clots on the collagen coated surface of glass plates after staining 
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5. Results and discussion 
In this study, various VWF concentrates were tested under the same conditions. In 
this experiment the coated glass plates simulated the ruptured vessel wall of a 
human body. The flow chamber itself built the blood vessel and the pump 
simulated the shear stress of a ruptured vessel wall. The samples consisted of 
erythrocytes, platelets, buffer solution and the VWF sample to simulate human 
blood at the physiologic pH value of 7.35. The following results show that 
different types of VWF bind differently to the collagenous surface. 
In the following figures the experiments were named after the date of the blood 
donation, such as bd060831, where “bd” stands for blood donor and “060831” 
stands for August 31, 2008. The %-Coverage refers to the clot-covered glass plate 
surface values calculated with the image processing computer programme 
(Digitrace). 
 
5.1. Differences in VWF bindings 
All the following results are blank corrected and averaged. In the graphs, each 
point shows the mean value of various experiments, which were carried out on 
different days using different erythrocytes- and platelet concentrates from 
different donors. The experiments were always carried out in the same way for all 
samples. 
 
5.1.1. VWF/factor VIII-Concentrate (Immunate#09HZ2000I) 
Immunate#09HZ2000I is a sterile, lyophilised, double-virus-inactivated plasma-
derived high-purity human VWF/factor VIII complex. Immunate#09HZ2000I is 
manufactured from pooled human plasma. Each individual plasma donation is 
screened with approved tests for Hepatitis B surface antigen (HBsAg), and for 
antibodies to HIV-1/HIV-2, and HCV, to prevent later infections using the 
Immunate#09HZ2000I concentrate [10]. The experiment was carried out as 
described in Section 4.4. Three concentrations of the VWF/factor VIII-
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concentrate were tested: (a) 0.5 U/ml, (b) 1 U/ml, and (c) 2 U/ml. The tables 
containing the numeric results for the tested VWF/factor VIII-concentrate can be 
found in Chapter 7.1.  
Figure 14 summarises the results of all experiments with the VWF/factor VIII-
concentrate. All data was blank corrected and averaged. The graph shows that the 
platelet adhesion properties of the VWF/factor VIII-concentrate at the 
concentration of 0.5 U/ml are mainly between 10% and 15%, whereas at a 
concentration of 1.0 U/ml, the platelet adhesion property is between 17% and 
20%. Finally, at the concentration of 2.0 U/ml the platelet adhesion property is 
between 20% and 27%. Two experiments (bd060831 and bd060808) differed 
significantly from the others, which may be due to the fact that the blood donors 
were anonymous. Hence, any blood coagulation inhibiting drugs, such as aspirin 
or others, influence the experiment and the herewith tested platelet adhesion 
ability of the samples under test. These problems could be avoided in future by 
establishing an adequate group of donors, where their anamneses are known. 
Also, the experiment bd060822 showed an unusual drop at the concentration of 
1.0 U/ml, which could be due to leakage of the flow chamber during the 
experiment, or, as mentioned above, individual differences in the blood 
concentrate. All in all, it was observed that the platelet adhesion ability of the 
VWF/factor VIII-concentrate Immunate#09HZ2000I increased with higher 
concentration. 
Although Immunate#09HZ2000I is not a single VWF concentrate, but also 
contains factor VIII, it was used as reference for all other experiments, because of 
its relatively high platelet adhesion properties. 
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Figure 14. Results for Immunate#09HZ2000I 
 
5.1.2. Pro-recombinant VWF 298 (Pro-rVWF 298) 
The VWF 298 is a recombinant Pro-VWF molecule. The recombinant Pro-VWF 
298 (Pro-rVWF 298) was produced using a proprietary blood-free technology and 
was subsequently purified.  
Figure 15 summarises the results of all experiments using the Pro-rVWF 298 
concentrate. At a concentration of 0.5 U/ml, the platelet adhesion ability of the 
Pro-rVWF lies in-between 4% and 6.5%, whereas at the concentration of 1.0 
U/ml all the results are approximately 8%. Finally, at the concentration of 2.0 
U/ml the results are almost equally at 10%. It could also be observed that at the 
concentration of 0.5 U/ml, the results are more spread than at the other two 
concentrations. The curve bd061011 showed an uncharacteristically low result, 
which may be due to the individual differences of the blood donors.  
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Figure 15.  Results for Pro-rVWF 298 
 
5.1.3. Mature recombinant VWF 158 (mature-rVWF 158) 
The VWF 158 is a mature, recombinantly processed VWF [12]. The mature 
subunits contain the binding sites for factor VIII, collagen, platelets and heparin. 
The recombinant mature-VWF 158 was also processed without the use of human 
blood and then purified. 
In Figure 16 the results for the mature-rVWF 158 are shown. At the 
concentrations of 0.5 U/ml and 1.0 U/ml, the curves bd060919 and bd060927 
show similar results, whereas at the concentration of 2.0 U/ml, the result range 
lies between 12% and 16%. The results of curve bd060808 are clearly lower than 
the other two, which again may be due to the fact that the blood donors were 
anonymous and the results my have been influenced by blood coagulation 
inhibiting drugs. 
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Figure 16. Results for mature-rVWF 158 
  
 
5.1.4. Plasma-derived VWF 09 (pd-VWF 09) 
The VWF 09 was plasma-derived from human plasma and subsequently virally 
inactivated. The results for pd-VWF 09 at the concentration of 0.5 U/ml are at 
10%, whereas at the concentration of 1.0 U/ml of pd-VWF 09, the results are at 
14%. At the concentration of 2.0 U/ml the platelet adhesion abilities of the pd-
VWF 09 are at 20%, which is shown in Figure 17. 
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Figure 17. Results for the pd-VWF 09 
 
5.1.5. Plasma-derived VWF 07 42/3 (pd-VWF 07 42/3) 
The VWF 07 42/3 is a plasma-derived and virally inactivated human VWF. As 
Figure 18 shows, the results for the platelet adhesion ability of the pd-VWF 07 
42/3 at the concentration of 0.5 U/ml are between 5% and 7%. At the 
concentration of 1.0U/ml only the results of the experiments bd060919 and 
bd060927 are quite similar and lie at 7%. These two also compare at the 
concentration of 2.0 U/ml at approximately 10%.The curve bd060808 shows an 
uncharacteristic drop at the concentration of 1.0 U/ml and is also far below the 
other curves at the concentration of 2.0 U/ml, which again could be due to the 
anonymous blood donors. However, the curve bd060822 shows an 
uncharacteristically high platelet adhesion value of 19% at the concentration of 
2.0 U/ml. 
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Figure 18. Results of pd-VWF 07 42/3 
 
5.2. Influence of factor VIII in VWF binding 
The motivation for these experiments was to determine if clot forming is 
increased or diminished when factor VIII is added. For these experiments, VWF 
concentrates as well as factor VIII concentrates were mixed and the flow chamber 
experiment was carried out as described in 4.4.5. 
 
5.2.1. Pro-rVWF 298 and factor VIII 
In these experiments the Pro-rVWF 298 was either mixed with a plasma-derived 
factor VIII concentrate, or with a recombinant factor VIII concentrate. As Figure 
19 shows, the platelet adhesion properties of the Pro-rVWF 298 were marginally 
influenced by the addition of the factor VIII concentrates. The curves bd060926, 
bd061017 and bd061018 show the results for the Pro-rVWF 298 without the 
addition of factor VIII as described in 5.1.2. They show approximately equal 
results at each of the three concentrations used. The Pro-rVWF 298 was the 
mixed with a plasma-derived factor VIII (pd-factor VIII) concentrate (1:1) and 
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the results for this experiment are shown in the curve bd061129pdFVIII. The 
values for the platelet adhesion properties at 0.5 U/ml and 1.0 U/ml are somewhat 
lower than the ones without the pd-factor VIII. In contrast, the recombinant factor 
VIII/Pro-rVWF 298 mixture showed a slightly higher platelet adhesion property 
than the Pro-rVWF 298 concentrate alone as exemplified by curve 
bd061018rFVIII. Note that the results from this experiment have a large variance 
due to various influences, such as anonymous blood donors. 
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Figure 19.  Results of  Pro-rVWF with and without different factor VIII 
concentrates 
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5.2.2. Mature-rVWF 158 and factor VIII  
The mature-rVWF 158 was tested with a plasma-derived factor VIII and also a 
recombinant factor VIII. As Figure 20 shows, the platelet adhesion properties of 
the mature-rVWF 158 were not significantly influenced by the addition of neither 
the plasma-derived factor VIII nor the recombinant factor VIII as shown in curves 
bd061128pdFVIII and bd061128rFVIII. 
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Figure 20. Results for the mature-rVWF 158 with and without factor VIII 
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5.2.3. Plasma-derived VWF 09 and factor VIII  
In Figure 21 the results for the plasma-derived VWF 09 with and without the 
addition of either recombinant factor VIII or plasma-derived factor VIII are 
shown. In the curves, no effect of factor VIII can be seen. All results are in the 
same fluctuation range. Thus, the results of this test are not conclusive regarding 
the influence of factor VIII in the plasma-derived VWF 09 platelet adhesion 
properties. 
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Figure 21. Results for the plasma-derived VWF 09 
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5.3. Competition experiment 
The aim of this experiment was to investigate subtractive or additive effects in the 
platelet adhesion abilities, when two different VWF concentrates were mixed. For 
this experiment the plasma-derived VWF 09 and the VWF SEC 06 were used. 
Three different mixtures were tested: (a) 50% (V/V) of pdVWF 09 and 50% 
(V/V) of VWF SEC 06, (b) 25% (V/V) and 75% (V/V), respectively, and (c) 75% 
(V/V) and 25% (V/V), respectively. In Figure 22 the results of this study are 
summarised. In comparison to the VWF SEC 06 alone, the mixtures showed a 
significantly higher platelet adhesion property, aside from the concentration 0.5 
U/ml, where the 50% : 50% mixture showed the lowest values. All in all, it turns 
out that the combination of different VWF concentrates may increase the platelet 
adhesion properties of the mixture. 
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Figure 22. Results of the competition experiment 
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5.4. Comparison and discussion 
 
 
The following results were obtained by the method described in Section 4.3. In 
Figure 23 all the VWF concentrates are summarised. The plasma-derived 
VWF/factor VIII concentrate (Immunate#09HZ2000I) and the plasma-derived 
VWF 09 (pd-VWF 09) performed best; their platelet adhesion properties at a 
concentration of 2.0 U/ml are at 25% and at 20%. The fact that the Immunate 
concentrate performed best was to be expected, because in [9] the authors have 
already found out the Immunate concentrate showed remarkable results in clinical 
trials.  
In contrast, the pro-recombinant VWF 298 (pro-rVWF 298) lead to the lowest 
results in binding to the collagen-coated surface. The fact that the Pro-rVWF 
concentrates showed the lowest platelet adhesion properties, may be due to a 
diminished Pro-VWF/factor VIII binding. As pointed out in [13] the Pro-VWF 
molecule showed lower binding affinity for factor VIII, which may be due to 
either not accessible binding sites on the VWF protein, or an altered affinity to 
these specific binding sites. In [11] the authors discuss that the Pro-VWF protein 
failed to mediate platelet adhesion. They also pointed out that multimerisation is 
required for VWF to attain functional GPIb binding. The presence of uncleaved 
VWF propeptide inhibits both factor VIII binding and its stabilisation. 
In [14] the author described the advantages of recombinant VWF in comparison 
to the plasma–derived VWF. Several limitations connected with the plasma-
derived VWF, such as proteolytic degradation during the manufacturing process 
or variation in multimer composition and also donor dependence could be 
overcome by recombinant processing. Also the risk of infection with HIV or 
Hepatitis can be excluded using recombinant VWF for therapy. In contrast to the 
findings in [14], the recombinant VWF concentrates used in these experiments 
did not perform nearly as well as the plasma-derived ones.  In [14] the author also 
discussed that the platelet adhesion properties of VWF are dependent on the 
degree of multimerisation of the VWF protein. The pro-rVWF is mostly a dimer 
having a low multimerisation degree. In contrast to the pro-rVWF, the plasma-
derived VWF concentrates intrinsically have a high multimerisation degree which 
is supposed to lead to higher platelet adhesion properties. The multimerisation 
degree of the mature-rVWF protein is yet unknown, but it is believed to be in the 
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same range as the plasma-derived VWF concentrates. This is reflected in the 
results presented in this diploma thesis, where the mature-rVWF showed better 
platelet adhesion properties than the pro-rVWF (see Figure 23). 
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Figure 23. Comparison of all VWF-samples 
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Figure 24.  Comparison of platelet binding properties of all VWF samples in 
presence and absence of  recombinant or plasma-derived factor VIII 
 
 
In Figure 24 all the results regarding all combinations of VWF concentrates 
(plasma-derived and recombinant) and factor VIII addition (plasma-derived and 
recombinant) are summarised. Interestingly, all the VWF/factor VIII mixtures 
showed lower platelet adhesion properties than the respective VWF concentrates 
alone, except for the Pro-recombinant VWF 298 (pro-rVWF 298). There, the 
mean values for the pro-rVWF 298 in mixture with the recombinant factor VIII 
are slightly higher than the VWF concentrate alone or in mixture with the plasma-
derived factor VIII. Due to few problems concerning the flow chamber and the 
calculation programme, which are summarised in Section 5.5, this result may not 
be significant.  
Another problem that may play a major role regarding the scattered results is the 
fact that the blood used, came from different donors. The donors were also 
anonymous, which means that their anamneses were also unknown. So, the 
influence of different drugs, probably taken before the blood donation, could not 
be investigated in these experiments. It must be said that blood coagulation 
inhibitors or various cyclooxygenase inhibitors, such as Aspirin, also affected the 
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results severely. So for further investigation and to verify the results, a specific 
group of donors would be beneficial.  
All in all, it turns out that the best platelet adhesion properties can be expected 
using the pd-VWF/factor VIII concentrate (Immunate#09HZ2000I) or the pd-
VWF 09.  
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Figure 25. Comparison of all VWF samples with and without factor VIII (mean 
value) 
 
 
Figure 25 shows the mean results obtained with different VWF concentrates alone 
in comparison to the mean results obtained with the VWF/factor VIII 
concentrates. In this graph, the origin of the factor VIII concentrates was not 
accounted for. The plasma-derived and the recombinant factor VIII concentrate 
values were combined and averaged. Again, it can be clearly seen that the pd-
VWF concentrate Immunate#09HZ2000I performed best. However, the addition 
of factor VIII to the VWF concentrates showed no specific increase of the platelet 
adhesion properties of the concentrates. This leads to the conclusion that the 
addition of factor VIII does not significantly influence the VWF-induced platelet 
adhesion properties. Thus, for patients suffering from both VWD and decreased 
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factor VIII levels, factor VIII can be added to VWF concentrates, without 
compromising the platelet adhesion assisted by the VWF.  
 
 
 
 
5.5. Difficulties concerning the flow-chamber experiment 
 
The problem interpreting these results is that the blank values often ranged from 
8% to 12% of the collagen-coated-glass-plate coverage. This means that the 
unspecific binding of the platelets to the collagenous surface without the addition 
of any VWF was relatively high. This is particularly problematic for small values 
of the platelet adhesion property, since a high blank correction leads to 
questionable results. Also, by slight unpredictable leakage of the flow chamber, 
the programmed shear stress rates slightly differed. This effect led to a lower 
platelet adhesion.  
Furthermore, the clots on the collagenous surface of the glass plates were not 
always uniformly distributed, which means that some parts were heavily covered 
with blood clots, while others were not. Due to that fact, the evaluation was 
uncertain at some points because the computer was programmed to take photos 
every couple of millimetres. Therefore, some pictures contained less clots than 
others and the programme calculated too low glass plate coverage. For that reason 
some of the results differed strongly.  
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6. Conclusion 
 
 
In this diploma thesis, the platelet adhesion properties of five different VWF 
concentrates produced by Baxter Bioscience were tested. Also, the effect of factor 
VIII addition to the VWF concentrates was investigated.  
It turned out that the plasma-derived VWF/factor VIII concentrate 
(Immunate#09HZ2000I) showed the highest platelet adhesion properties. This 
concentrate was also rates as excellent or good results in clinical efficacy tests [9]. 
Only for patients with additional factor XIII deficiency the concentrate failed to 
perform well. 
 
Concentrates where recombinant or plasma-derived factor VIII was manually 
added to the VWF solution did not perform as well.  
The worst performance was observed with Pro-rVWF 298, independent of the 
addition of factor VIII, which is consistent to the results presented in [11], where 
the authors discussed that deletion of the vWF propeptide produced a dimeric 
VWF molecule that failed to mediate platelet agglutination, suggesting that 
multimerization is required for vWF to attain functional GPIb binding. They 
eventually found that the presence of uncleaved VWF propeptide inhibits both 
factor VIII binding and stabilization. 
Also generally, it was observed that the addition of factor VIII did not 
significantly influence the results obtained by pure VWF concentrates. However, 
this result might be compromised by the large variation in the blood samples. 
 
A number of difficulties were encountered in the experiments: 
Every experiment was conducted with blood from different donors. The fact that 
the anamneses of the blood donors were unknown led to widely scattered results. 
For future experiments it is necessary to select a suitable group of donors with 
known anamneses. In this way one could systematically avoid drug interactions 
with blood coagulation in the experiment, leading to more reproducible results. 
During the experiments, also a few shortcomings of the test system were 
encountered, which sometimes led to questionable results. To improve the 
significance of the results, both the flow chamber and the detection method need 
to be improved. 
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The flow chamber can be made leak proof by using a screw-top, which would be 
better suited than the clip-on spring. To avoid the glass plates from breaking, 
plastic plates are suggested.  
To solve the problem of the counting of the clots, a different detection method 
should be considered. One possibility is radio labelling the platelets or the VWF 
molecules and detecting the clots on the glass plates via a gamma-counter. 
Another method would be to label the platelets or the VWF molecules with 
fluorescent substances and detect the clots with a fluorescence detector. These 
methods exclude the problem of taking photos from non-uniformly covered areas.  
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7. Appendix 
 
7.1. Detailed results 
The next pages present the detailed results from all experiments. 
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Date Filenumber Concentration Platenumber %-Coverage Mean Blank Blank_corrected
9,846
08.08.2006 bd060808 2 6 25,861
2 7 24,845 25,353 15,507
1 16 17,455 17,455 7,609
0,5 21 17,406 17,406 7,560
11,781
22.08.2006 bd060822 2 67 34,369
2 68 33,709 34,039 22,258
1 72 21,496
1 75 19,788 20,642 8,861
0,5 16 22,527
0,5 17 23,325 22,926 11,145
8,596
30.08.2006 bd060830 2 9 33,549
2 10 33,595
2 11 34,064
2 13 31,163 33,093 24,497
1 15 26,843
1 30 25,964
1 31 28,886 27,231 18,635
0,5 21 19,264
0,5 23 17,652
0,5 25 20,842
0,5 37 23,336 20,274 11,678
15,826
31.08.2006 bd060831 2 40 36,767
2 42 31,268
2 44 34,408 34,148 18,322
1 25 27,111
1 24 24,107
1 29 28,100 26,439 10,613
0,5 20 22,836
0,5 26 24,967
0,5 27 21,123 22,975 7,149
10,138
26.09.2006 bd060926 2 5 34,204
2 6 35,818 35,011 24,873
1 7 32,421
1 8 29,587 31,004 20,866
0,5 12 23,260 23,26 13,122
10,123
03.10.2006 bd061003 2 26 33,770
2 27 34,954 34,362 24,239
1 14 28,663
1 10 28,948 28,8055 18,683
0,5 18 22,513
0,5 22 22,965 22,739 12,616
Immunate#09HZ2000l - VWF- Factor VIII- Concentrate
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9,951
11.10.2006 bd061011 2 71 37,145 37,145 27,194
1 67 30,003 30,003 20,052
0,5 64 25,117 25,117 15,166
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Date Filenumber Concentration Platenumber %-Coverage Mean Blank Blank_corrected
10,138
26.09.2006 bd060926 2 29 22,654
2 30 18,363
2 20 19,000
2 21 16,344 20,006 9,868
1 22 17,791
1 24 18,358
1 31 16,992
1 32 20,079 17,714 7,576
0,5 27 17,534
0,5 28 16,209
0,5 33 16,865 16,537 6,399
10,123
03.10.2006 bd061003 2 35 22,124
2 36 18,116
2 38 20,120 9,997
1 39 18,374
1 40 17,776
1 41 18,075 7,952
0,5 43 13,758
0,5 44 14,894
0,5 45
0,5 46 14,326 4,203
9,951
11.10.2006 bd061011 2 57 15,985
2 58 16,418 16,202 6,251
1 51 14,154
1 56 14,858 14,506 4,555
0,5 46 14,218
0,5 47 14,124 14,171 4,220
4 52 18,421 18,421 8,470
8 55 16,721
9,739
17.10.2006 bd061017 2 63 22,174
2 64 16,918 19,546 9,807
1 65 15,895
1 67 19,503 17,699 7,960
0,5 68 15,692
0,5 69 16,832 16,262 6,523
7,377
18.10.2006 bd061018 2 95 14,283
2 96 16,809 16,809 9,432
1 97 14,789
1 98 15,354 15,072 7,695
0,5 101 13,257
0,5 102 13,162 13,210 5,833
Pro-rVWF 298 
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7,377
18.10.2006 bd061018FVIII 2 11 15,176
2 12 17,481 17,481 10,104
1 14 15,849 15,849 8,472
0,5 99 13,928
0,5 100 13,715 13,822 6,445
6,739
29.11.2006 bd061129 2 28 15,787
2 30 15,351 15,569 8,830
1,5 31 13,819
1,5 32 12,670 13,245 6,506
1 34 11,971
1 35 12,399 12,185 5,446
0,5 36 11,414
0,5 38 11,062 11,238 4,499
Pro-rVWF 298 & r-factor VIII
Pro-rVWF298 & pd-factor VIII
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Date Filenumber Concentration Platenumber %-Coverage Mean Blank Blank_corrected
9,846
08.08.2006 bd060808 2 46 15,919
2 47 17,258 16,589 6,743
1 50 14,329
1 49 15,762 15,046 5,200
0,5 52 14,297
0,5 51 12,913 13,605 3,759
10,202
19.09.2006 bd060919 2 11 23,272
2 11 24,747
2 13 21,190
2 13 19,517 22,600 12,398
1 16 20,327
1 16 22,277
1 17 19,360
1 17 21,224 20,797 10,595
0,5 24 15,156
0,5 24 18,578
0,5 25 20,276
0,5 25 17,533 17,886 7,684
9,844
27.09.2006 bd060927 2 37 27,087
2 38 26,955
2 39 25,416 26,486 16,642
1 42 21,209
1 51 20,552
1 52 22,388 21,383 11,539
0,5 48 17,740
0,5 49 18,181
0,5 50 19,731 18,551 8,707
6,546
24.10.2006 bd061024 2 34 23,312
2 36 17,666 23,312 16,766
1 37 17,790
1 38 15,930 16,860 10,314
0,5 39 15,016
0,5 40 12,532 13,774 7,228
mature-rVWF 158
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6,739
28.11.2006 bd061128 2 10 22,758
2 11 23,079 22,919 16,180
1 13 17,372
1 14 14,790 16,081 9,342
0,5 15 14,633
0,5 17 13,311 13,972 7,233
6,739
28.11.2006 k061128 2 41 22,689
2 40 broken 22,689 15,950
1,5 45 19,129
1,5 46 18,450 18,790 12,051
1 47 15,702
1 48 16,030 15,866 9,127
0,5 49 13,322
0,5 50 10,500 11,911 5,172
mature-rVWF 158 & r-factor VIII
mature-rVWF 158 & pd-factor VIII
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Date Filenumber Concentration Platenumber %-Coverage Mean Blank Blank_corrected
9,739
17.10.2006 bd061017 2 48 29,318
2 49 28,058
2 50 34,391
2 51 27,415 29,796 20,057
1 52 26,094
1 53 23,677
1 54 24,472
1 55 23,869 24,528 14,789
0,5 56 21,298
0,5 57 17,096
0,5 61 22,867
0,5 62 18,196 19,864 10,125
6,546
24.10.2006 bd061024 2 3 31,885
2 4 30,730
2 6 30,910
2 7 31,652 31,294 24,748
1 8 26,788
1 9 23,777
1 10 24,747
1 11 29,692 25,104 18,558
0,5 12 21,043
0,5 13 22,169
0,5 14 21,664
0,5 15 18,466 20,836 14,290
6,080
21.11.2006 bd061121 2 43 32,670
2 44 30,664 31,667 25,587
1,5 41 26,564
1,5 42 26,203 26,384 20,304
1 39 23,997
1 40 23,929 23,963 17,883
0,5 38 18,196 18,196 12,116
Plasma-derived VWF 09
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9,739
17.10.2006 bd061017 2 73 30,908
2 76 27,434
2 83 31,082
2 84 27,848 29,318 19,579
1 79 24,685
1 86 23,898
1 87 22,977 23,853 14,114
0,5 80 18,882
0,5 82 18,265
0,5 85 18,752
0,5 89 20,109 19,002 9,263
6,546
24.10.2006 bd061024 2 16 30,603
2 17 30,673 30,638 24,092
1 19 24,458
1 20 23,183 23,821 17,275
0,5 21 19,474
0,5 22 16,310 19,474 12,928
6,739
28.11.2006 bd061128 2 18 30,002
2 19 28,222 29,112 22,373
1,5 22 25,176
1,5 23 25,150 25,163 18,424
1 24 24,231
1 25 23,681 23,956 17,217
0,5 26 16,222
0,5 27 13,417 16,222 9,483
pd-VWF09 and r-factor VIII
pd-VWF09 and pd-factor VIII
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Date Filenumber Concentration Platenumber %-Coverage Mean Blank Blank_corrected
9,846
08.08.2006 bd060808 2 23 14,578
14,578 4,732
1 25 10,301
10,301 0,455
0,5 29 18,901
0,5 30 19,117 19,009 9,163
11,781
22.08.2006 bd060822 2 18 30,879
2 19 32,300 31,590 19,809
1 20 27,282
1 21 26,546 26,914 15,133
0,5 24 19,182
0,5 30 18,786 18,984 7,203
10,202
19.09.2006 bd060919 2 46 25,071
2 46 24,842
2 48 21,306
2 48 19,702 23,131 12,929
1 49 20,554
1 49 17,672
1 50 18,258
1 50 18,810 19,544 9,342
0,5 51 16,851
0,5 51 18,008
0,5 53 17,797
0,5 53 16,393 17,262 7,060
9,844
27.09.2006 bd060927 2 58 21,010 21,010 11,166
1 55 18,556
1 62 18,767 18,662 8,818
0,5 66 18,778
0,5 69 15,629 15,629 5,785
Plasma-derived VWF 07 42/3
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7.2. Figure sources 
 
Figure 1. List of clotting factors involved in the blood coagulation  
(http://www.uta.edu/biology/henry/classnotes/2458/Clotting%20F
actors.jpg) 
Figure 2.  Reaction cascade of blood coagulation 
(http://medicaldictionary.thefreedictionary.com/_/viewer.aspx?pat
h=dorland&name=pathway_coagulation.jpg) 
Figure 3.  Blood clot 
(http://dept.physics.upenn.edu/~aebrown/biocurious/clot-and-
fiber.jpg) 
Figure 4.  Genesis of platelets 
(http://training.seer.cancer.gov/ss_module08_lymph_leuk/images/i
llu_blood_cell_lineage.jpg) 
Figure 5.  Activated platelets  
(http://www.sciencehelpdesk.com/img/bg3_2/Platelets1.jpg) 
Figure 6.  VWF binding platelets to collagen  
(http://www.orthosupersite.com/images/content/obj/0803/kroonen
_fig1.gif) 
Figure 7.  Structure of the von Willebrand factor  
(http://www.VWF.group.shef.ac.uk/graphics/protein.jpg) 
Figure 8.  Ribbon drawings of (a) the crystal structure of the collagen binding 
VWF-A3 domain; (b) Schematic representation of the complex of 
GpIb  (green) and the VWF-A1 domain (blue).  
(http://www.crystal.chem.uu.nl/group-huizinga/a3-nolab.jpg, 
http://www.esrf.eu/UsersAndScience/Publications/Highlights/2002
/MX/MX3/fig005)  
Figure 9.  Resemblance of factor VIII and factor V,  
(http://blood.uvm.edu/lab/domains.jpg)  
Figure 10.  Haematocrit and Platelet count  
Figure 11.  Preparation of the flow chamber  
Figure 12.  Set up of the flow chamber experiment 
Figure 13.  Blood clots on the collagen coated surface of glass plates after 
staining 
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Figure 14.  Results for Immunate#09HZ2000I  
Figure 15.   Results for Pro-rVWF 298 
Figure 16.  Results for mature-rVWF 158 
Figure 17.  Results for the pd-VWF 09 
Figure 18.  Results of pd-VWF 07 42/3 
Figure 19. Results of Pro-rVWF with and without different factor VIII 
concentrates 
Figure 20. Results for the mature-rVWF 158 with and without factor VIII 
Figure 21.  Results fort he plasma-derived VWF 09 
Figure 22.  Results of the competition experiment 
Figure 23.  Comparison of all VWF-samples 
Figure 24.   Comparison of all VWF samples with and without recombinant or 
plasma-derived factor VIII 
 
Figure 25.  Comparison of all VWF samples with and without factor VIII 
(mean value) 
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7.3. Abbreviations 
 
 
VWF von Willebrand factor 
VWD von Willebrand disease 
FVIII factor VIII 
pd plasma-derived 
DNA deoxyribonucleic acid 
Ca2+ Calcium 
Na/Cl sodium chloride 
HCT haematocrit 
COX-1 Cycolooxygenase-1 
U/ml (Antigen-) Units per millilitre 
ml  millilitre 
µl microlitre 
mM millimolar 
rpm rotations per minute 
°C degree centigrade  
w/o without 
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Kletter, M. Mitterhauser, W. Wadsak, „The Dilemma Using Log P to Define 
Lipophilicity of PET Tracers”, poster presentation at EANM Conference, 
Munich, Oct 2008 
[6] D.E. Ettlinger, W. Wadsak, K. Sindelar (presenter), L.K. Mien, D. Haeusler, 
R. Lanzenberger, R. Dudczak, K. Kletter, M. Mitterhauser, 
„[18F]Fluoroethylated radiotracers: Metabolic considerations“, oral 
presentation at ÖGN Conference, Bad Hofgastein, Jan 2008 
 
Besondere Qualifikationen: 
 
Laborerfahrung: Blut-Hirn-Schranken-Modelle (Log P 
Modelle) 
HPLC Analysen (Metaboliten, Log P) 
Herstellung von PET Tracern 
Dielektrophorese von Bakterien und Zellen 
Flusskammer 
 
Fremdsprachen: Cambridge Certificate of Proficiency 
4 Sprachendiplom bei Berlitz (2008): 
  - Englisch (perfekt in Wort und 
Schrift) 
  - Russisch (Grundkenntnisse) 
  - Französisch (sehr gut in Wort und 
Schrift) 
  - Italienisch (gut in Wort und Schrift) 
 Spanisch (Grundkenntnisse) 
      
Führerschein:    Klasse B seit Oktober 2001 
 
 
 
Computerkenntnisse:   Microsoft Windows und Office Kenntnisse 
     Grundlegende PC-Hardwarekenntnisse 
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